1. OS01.5.A Neuron-specific enolase (NSE) and S100 serum levels in patients with active brain metastases from HER2-positive breast cancer treated with trastuzumab-deruxtecan (T-DXd): A biomarker analysis from the TUXEDO-1 trial. (5th September 2022) Authors: Berghoff, A S; Bartsch, R; Furtner, J; Marhold, M; Bergen, E S; Roider-Schur, S; Starzer, A M; Forstner, H; Rottenmanner, B; Dieckmann, K; Bago-Horvath, Z; Widhalm, G; Ilhan-Mutlu, A; Minichsdorfer, C; Fuereder, T; Singer, C F; Weltermann, A; Haslacher, H; Szekeres, T; Puhr, R Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OS1.1 Plasma PD-L1 levels over time differ between glioblastoma and lower-grade glioma patients. (6th September 2019) Authors: Mair, M; Ilhan-Mutlu, A; Pajenda, S; Widhalm, G; Dieckmann, K; Hainfellner, J A; Marosi, C; Wagner, L; Preusser, M; Berghoff, A S Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 3 Page Start: iii5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P-243A comparison of the utilization and efficacy of palliative chemotherapy for the treatment of locally advanced or metastatic gastroesophageal carcinoma: a retrospective single-center analysis. (2nd July 2019) Authors: Baumgartner, R; Taghizadeh, H; Jomrich, G; Schoppmann, S; Preusser, M; Ilhan-Mutlu, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗